Drug - Adempas® (riociguat) [Bayer HealthCare Pharmaceuticals Inc.]
Therapeutic area - Pulmonary arterial hypertension (PAH); Chronic thromboembolic pulmonary hypertension (CTEPH)
- Patient has a diagnosis of PAH OR
- Patient has a diagnosis of CTEPH
Quantity limit = 102 tablets (all strengths).
Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with Pulmonary Arterial Hypertension (PAH) or Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.
MHCP Provider Call Center 651-431-2700 or 800-366-5411